SOPHiA GENETICS announced a further expansion of its collaboration with AstraZeneca, focusing on improving the diagnosis and treatment of breast and prostate cancer. The companies aim to develop an optimized next-generation sequencing (NGS) solution that leverages SOPHiA GENETICS' AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.
The PIK3CA/AKT1/PTEN pathway is a critical molecular signaling network linked to the development of many cancers, including breast and prostate cancer. A prototype of the enhanced solution has already demonstrated improved sensitivity in detecting complex mutations across this pathway.
As part of the agreement, SOPHiA GENETICS will initiate a Privileged Access Program with selected clinical laboratories specializing in breast and prostate cancer research for validation. Broader commercial availability of this advanced solution is expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness, with SOPHiA's global network driving adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.